Change search
ReferencesLink to record
Permanent link

Direct link
Connecting Inflammation with Glutamate Agonism in Suicidality
Karolinska Institute, Sweden .
University of New S Wales, Australia .
Karolinska Institute, Sweden .
Lund University, Sweden .
Show others and affiliations
2013 (English)In: Neuropsychopharmacology, ISSN 0893-133X, E-ISSN 1740-634X, Vol. 38, no 5, 743-752 p.Article in journal (Refereed) Published
Abstract [en]

The NMDA-receptor antagonist ketamine has proven efficient in reducing symptoms of suicidality, although the mechanisms explaining this effect have not been detailed in psychiatric patients. Recent evidence points towards a low-grade inflammation in brains of suicide victims. Inflammation leads to production of quinolinic acid (QUIN) and kynurenic acid (KYNA), an agonist and antagonist of the glutamatergic N-methyl-D-aspartate (NMDA) receptor, respectively. We here measured QUIN and KYNA in the cerebrospinal fluid (CSF) of 64 medication-free suicide attempters and 36 controls, using gas chromatography mass spectrometry and high-performance liquid chromatography. We assessed the patients clinically using the Suicide Intent Scale and the Montgomery Asberg Depression Rating Scale (MADRS). We found that QUIN, but not KYNA, was significantly elevated in the CSF of suicide attempters (Pandlt;0.001). As predicted, the increase in QUIN was associated with higher levels of CSF interleukin-6. Moreover, QUIN levels correlated with the total scores on Suicide Intent Scale. There was a significant decrease of QUIN in patients who came for follow-up lumbar punctures within 6 months after the suicide attempt. In summary, we here present clinical evidence of increased QUIN in the CSF of suicide attempters. An increased QUIN/KYNA quotient speaks in favor of an overall NMDA-receptor stimulation. The correlation between QUIN and the Suicide Intent Scale indicates that changes in glutamatergic neurotransmission could be specifically linked to suicidality. Our findings have important implications for the detection and specific treatment of suicidal patients, and might explain the observed remedial effects of ketamine. Neuropsychopharmacology (2013) 38, 743-752; doi:10.1038/npp.2012.248; published online 9 January 2013

Place, publisher, year, edition, pages
Nature Publishing Group: Open Access Hybrid Model Option A , 2013. Vol. 38, no 5, 743-752 p.
Keyword [en]
quinolinic acid, suicide, depression, glutamate, cytokine
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-91010DOI: 10.1038/npp.2012.248ISI: 000316161300004OAI: diva2:615668

Funding Agencies|Swedish Research Council|2009-42842011-47872002-52972008-29222009-70522011-4795|Province of Scania clinical state grants (ALF)||American Foundation for Suicide Prevention|2-DIG-00030-0608-1208|Rebecca Cooper Foundation||National Health Medical Research Council in Australia (NHMRC)||

Available from: 2013-04-11 Created: 2013-04-11 Last updated: 2014-10-30

Open Access in DiVA

fulltext(586 kB)103 downloads
File information
File name FULLTEXT01.pdfFile size 586 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Samuelsson, Martin
By organisation
PsychiatryFaculty of Health SciencesDepartment of Psychiatry
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 103 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 59 hits
ReferencesLink to record
Permanent link

Direct link